Cytodel, Inc.
New York, NY
- UEI
- C1AUXSRGH7W5
- CAGE
- 6VDS7
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 423 W 127th St, New York, NY 10027, USA
- Website
- cytodel.com
- Founded
- 2012
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Development of B8C1AD as an orphan drug for iatrogenic botulism - abstract botulinum neurotoxin serotype A1 (bont/A1)… | National Institute of Neurological Disorders and Stroke | $886,095 | |
| Recombinant botulinum toxin with improved safety and effectiveness for treatment of dystonia - abstract botulinum… | National Institute of Neurological Disorders and Stroke | $829,848 | |
| Post-symptomatic antidotes to botulinum neurotoxin(psabs) | Interior Business Center | $1,429,034 | |
| Recombinant botulinum neurotoxin for treatment of spastic disorders | National Institutes of Health | $223,940 |
About Cytodel, Inc.
Cytodel Inc. is a preclinical stage biopharmaceutical company that specializes in developing recombinant botulinum toxin (rBoT) derivatives. Their patented technology platform allows for the creation of antibody fusion proteins that can deliver therapeutic payloads inside neurons. Cytodel is registered as a Self Certified Small Disadvantaged Business and a For Profit Organization.
Through federal grant awards from the National Institutes of Health (NIH) National Institute of Neurological Disorders and Stroke, Cytodel has developed therapeutic candidates for botulinum neurotoxin overdose and safer botulinum neurotoxin derivatives for neuromuscular indications. One project aims to establish an animal model for botulinum neurotoxin serotype A1 overdose and develop B8C1AD, an antibody-botulinum toxin fusion protein, as an orphan drug treatment for iatrogenic botulism ($590,730 award). Another project focuses on testing CYTO-014, a recombinant botulinum neurotoxin A1 derivative designed to have improved safety over existing botulinum toxin pharmaceuticals while retaining efficacy, for treating dystonia ($829,848 award). Cytodel has also received a sub-award from an NYU prime grant to conduct murine testing of botulinum toxin antibodies and advance lead candidates like Cyto-111 towards development. Their work involves collaborations with prime grantees and US Army partners.
Quick answers
What is Cytodel, Inc.'s UEI?
Cytodel, Inc.'s Unique Entity ID (UEI) in SAM.gov is C1AUXSRGH7W5.
What is Cytodel, Inc.'s CAGE code?
Cytodel, Inc.'s CAGE code is 6VDS7.
What is Cytodel, Inc.'s primary NAICS code?
Cytodel, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Cytodel, Inc. located?
Cytodel, Inc.'s physical address in SAM.gov is 423 W 127th St, New York, NY 10027, USA.
Is Cytodel, Inc. registered in SAM.gov?
Yes. Cytodel, Inc.'s SAM.gov registration is active through May 21, 2027.
What is Cytodel, Inc.'s most recent federal award?
Cytodel, Inc.'s most recent federal grant award is Development of B8C1AD as an orphan drug for iatrogenic botulism - abstract botulinum neurotoxin serotype A1 (bont/A1)… (R43NS130849), from National Institute of Neurological Disorders and Stroke, on January 1, 2023.
On GovTribe
See Cytodel, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors